Floatz logo

FILGRASTIM

Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8

Mayo Clinicprotein_peptidePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8 cohort.

Asset / SponsorPhaseRating
Sargramostim
Mayo Clinic
Phase 1/2CCC
FLUTICASONE
Mayo Clinic
Phase 1/2CCC
Polyiclc
Mayo Clinic
Phase 1/2CCC

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →